A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
30/11/2015 | Plasma membrane protein array now tops 4,500: increasing chances of identifying specific receptor targets. Retrogenix today announces that it has expanded its human cell microarray technology to include an additional 1,000 cDNA clones. This brings the total number of plasma membrane... | Read More
Retrogenix will be attending the 9th Annual Proteins & Antibodies Congress on the 18th and 19th of April in London, UK | Find out more
"We are very pleased with the service Retrogenix provided to us. In less than two months they were able to identify and confirm the target specificity of multiple antibodies we provided to Retrogenix (over 70% of antibodies provided).This helped us to validate our internal technology development." | Read more
Professor Thomas Lavstsen, University of Copenhagen